Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021

Increasing life expectancy and maintaining its quality are the main goals of the hormone-dependent HER2-negative advanced breast cancer (HR+ HER2- аBC) therapy. A Satellite Symposium of Novartis Pharma was held on January 28th, 2021, within the framework of the RUSSCO Big Conference Breast Cancer. I...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Editorial Board
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	hormone-dependent her2-negative advanced breast cancer cdk4/6 inhibitors ribociclib overall survival quality of life Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/47732b8b0d2841bead79d5d3f5037738
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:47732b8b0d2841bead79d5d3f5037738
record_format	dspace
spelling	oai:doaj.org-article:47732b8b0d2841bead79d5d3f50377382021-11-30T16:55:00ZDon’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 20211815-14341815-144210.26442/18151434.2021.1.200764https://doaj.org/article/47732b8b0d2841bead79d5d3f50377382021-05-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/70299/51231https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Increasing life expectancy and maintaining its quality are the main goals of the hormone-dependent HER2-negative advanced breast cancer (HR+ HER2- аBC) therapy. A Satellite Symposium of Novartis Pharma was held on January 28th, 2021, within the framework of the RUSSCO Big Conference Breast Cancer. It was dedicated to the benefits of Risarg (ribociclib) therapy in combination with hormone therapy (HT). Experts-oncologists shared current data and their experience with ribociclib. The combination of CDK4/6 inhibitors with HT became a gold standard for the 1st line therapy for HR+ HER2- aBC. And the choice of a specific drug is based on the data of clinical studies and is made taking into account the individual characteristics of the patient. The results of ribociclib studies (MONALEESA-3 and MONALEESA-7) demonstrate a significant increase in the median overall survival and a decrease in the risk of death by 28 and 30%. The tolerance profile of ribociclib is well studied and controlled, therefore the risks of adverse events can be reduced by the competent monitoring, and the necessary dose modification can be made, which allows most patients to maintain highly effective therapy. The use of ribociclib allows to achieve the main goals of therapy to prolong the patients life and maintain or improve its quality.Editorial BoardIP Habib O.N.articlehormone-dependent her2-negative advanced breast cancercdk4/6 inhibitorsribocicliboverall survivalquality of lifeNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 1, Pp 53-60 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	hormone-dependent her2-negative advanced breast cancer cdk4/6 inhibitors ribociclib overall survival quality of life Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	hormone-dependent her2-negative advanced breast cancer cdk4/6 inhibitors ribociclib overall survival quality of life Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Editorial Board Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021
description	Increasing life expectancy and maintaining its quality are the main goals of the hormone-dependent HER2-negative advanced breast cancer (HR+ HER2- аBC) therapy. A Satellite Symposium of Novartis Pharma was held on January 28th, 2021, within the framework of the RUSSCO Big Conference Breast Cancer. It was dedicated to the benefits of Risarg (ribociclib) therapy in combination with hormone therapy (HT). Experts-oncologists shared current data and their experience with ribociclib. The combination of CDK4/6 inhibitors with HT became a gold standard for the 1st line therapy for HR+ HER2- aBC. And the choice of a specific drug is based on the data of clinical studies and is made taking into account the individual characteristics of the patient. The results of ribociclib studies (MONALEESA-3 and MONALEESA-7) demonstrate a significant increase in the median overall survival and a decrease in the risk of death by 28 and 30%. The tolerance profile of ribociclib is well studied and controlled, therefore the risks of adverse events can be reduced by the competent monitoring, and the necessary dose modification can be made, which allows most patients to maintain highly effective therapy. The use of ribociclib allows to achieve the main goals of therapy to prolong the patients life and maintain or improve its quality.
format	article
author	Editorial Board
author_facet	Editorial Board
author_sort	Editorial Board
title	Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021
title_short	Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021
title_full	Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021
title_fullStr	Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021
title_full_unstemmed	Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021
title_sort	don’t let it disappear: new opportunities to prolong the life of hr+ her2- advanced breast cancer patients. event review of the satellite symposium. russco big conference «breast cancer» (online). january 28th, 2021
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/47732b8b0d2841bead79d5d3f5037738
work_keys_str_mv	AT editorialboard dontletitdisappearnewopportunitiestoprolongthelifeofhrher2advancedbreastcancerpatientseventreviewofthesatellitesymposiumrusscobigconferencebreastcanceronlinejanuary28th2021
_version_	1718406442000580608

Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021

Ejemplares similares